albuterol (Armstrong Albuterol HFA) vs albuterol / budesonide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Armstrong Albuterol HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: April 2028 · NCT07426458 (registry estimate)
No aligned efficacy figure on record for this race.
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Reported efficacy
Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)
Result source: NCT05505734
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Armstrong Albuterol HFA) | albuterol / budesonide |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00667407 | 0.5 vs 0.6vs AS MDINCT037690902 other results
|
| Trough FEV1, change | —Not posted · NCT00667407 | 0.1 vs 0.0+0.1 vs placeboNCT038478963 other results
|
| ACQ-5, change | —Not posted · NCT00667407 | —Not posted · NCT06502366 |
| OCS dose reduction | —Not posted · NCT00667407 | —Not posted · NCT06502366 |
Severe exacerbations, annualised rate
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- albuterol / budesonide
- 0.5 vs 0.6vs AS MDINCT03769090
2 other results
- 0.1 vs 0.3 NCT05505734
- 0.1 vs 0.3 NCT05505734
Trough FEV1, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- albuterol / budesonide
- 0.1 vs 0.0+0.1 vs placeboNCT03847896
3 other results
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
ACQ-5, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- albuterol / budesonide
- —Not posted · NCT06502366
OCS dose reduction
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- albuterol / budesonide
- —Not posted · NCT06502366
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol (Armstrong Albuterol HFA): 0 of 4 rows · albuterol / budesonide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol / budesonide |
|---|---|
| Dropout rate | 9.9%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results11.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 28.2%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 3.6%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 7.8%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0.7%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results0.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 0.5%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0.5%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 5.2%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results3.8%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 3.1%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 2%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0%160/180 NCT06245551 · Phase 3 0% NCT05555290 · Phase 3 · registry result, not featured evidence 0% NCT04234464 · Phase 3 · registry result, not featured evidence 0%160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more results160/180 μg upper respiratory tract infection 5.4% covid-19 5.1% nasopharyngitis 3.7% NCT05505734 · Phase 3 · Asthma · phase 3 160/180 μg nasopharyngitis 7.6% (placebo 5.5%) headache 5.1% (placebo 7%) dysphonia 2% (placebo 0%) NCT03847896 · Phase 3 · Asthma · phase 3 80/180 μg nasopharyngitis 6.4% (placebo 5.5%) headache 4.9% (placebo 7%) upper respiratory tract infection 1.5% (placebo 1%) NCT03847896 · Phase 3 · Asthma · phase 3 160/180 bronchial irritation 1.6% (placebo 0%) diarrhoea 0% (placebo 1.6%) headache 0% (placebo 1.6%) NCT06245551 · Phase 3 anxiety 0% (placebo 1.7%) dyspnoea 0% (placebo 1.7%) NCT04234464 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol / budesonide
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 13 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · albuterol / budesonide's landscape